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Abstract  
OBJECTIVES: Deep-vein thrombosis (DVT) forms a major healthcare burden in Europe, but exact estimates 
concerning the economic burden on society are lacking. This study reports results from the PREFER in VTE study 
concerning resource utilization and absence from work in DVT patients.  
 
METHODS: The PREFER in VTE registry was a prospective, observational, multicenter study carried out in Europe 
(France, Italy, Spain, the UK, and DACH [Germany, Switzerland and Austria]), designed to provide data concerning 
treatment patterns, resource utilization, mortality and quality of life. Patients with a first-time and/or recurrent DVT, 
were recruited and followed for 12 months. Data about resource utilization concerns resource utilization related to 
DVT. Specifically, treatment pattern, re-hospitalization rate, length of hospital stay, ambulatory/office visit, and 
proportion of patients returning to work, were analyzed and presented. Subgroup analysis by country and active 
cancer were also conducted. The length of hospital stay was analyzed as a function of demographics, previous events 
and co-morbidities using zero-inflated binomial negative regression. Similarly, time until return to work was analyzed 
using Cox regression.  
 
RESULTS: A total of 2056 patients with DVT were recruited, with an average age of 60 years. Patients with active 
cancer were mostly treated with heparin (83.9%), while patients without active cancer were treated with 
combinations of heparin, VKA and DOACs. DOACs were less often used in Spain and Italy (<7.0%). Following the 
management of their initial DVT 20.5% of the patients with and 12.2% of patients without active cancer (n=88; n= 
1462) were hospitalized for on average 8.2 and 10.1 days, respectively. The hospitalization-rate was highest in Italy 
(16.7%) and lowest in France (7.7%). Furthermore, the average length of stay was highest in Italy (16.6 days) and 
lowest in DACH (5.2 days). Physician visits were highest in DACH (9.3), lowest in the UK (2.6). Of those working, 50% 
returned to work at 1 month; more than 30% did not return to work within the year.  
 
CONCLUSIONS: Medical treatment of DVT differed between patients with active cancer and those without. Post-VTE 
or VTE-related resource utilization differs remarkably between countries. Work-loss seems high, but questions may 
be raised concerning the causality due to the presence of co-morbidities. 
 
 
Key Words: Deep-vein thrombosis, burden of illness, Europe, healthcare resource utilization, return to work, work-
loss   
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Introduction 
Acute venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a 
common disorder with an annual incidence of approximately 1 or 2 cases per 1000 persons in the general population 
[1 ?3]. Patients with VTE have increased morbidity and mortality, at first related directly to these conditions but 
secondly also as a complication of underlying diseases such as cancer, medical conditions and surgical procedures 
[4].   
 
Most of the evidence concerning the burden of VTE has been generated in the United States (US); it has been 
estimated that 547,596 VTE events (hospitalized) occur annually among US adults (18 years and above) with 348,558 
DVT, and 78,511 PE with DVT events [5]. Moreover, a recent review estimated the costs associated with the annual 
incidence of VTE events at $7-10 billion each year (limited to direct medical cost only) [6]. More specifically, a cost 
modelling study estimated that US VTE annual costs (including indirect costs) range from $13.5 to 69.3 billion (2011 
US Dollars) with $4.5 to 39.3 billion of these costs being preventable if improved prophylaxis measures were put in 
place [7]. Publications on the burden of VTE in Europe are relatively scarce.  A previously published modeling study 
 ? based on the data from 6 European countries - estimated that 684,019 DVT events (new and recurrent) occur per 
annum in the EU, with a prevalence of610,138 post-thrombotic syndrome (PTS) patients. The number of VTE-related 
deaths was estimated at 543,454 across the EU per annum [3]. The annual VTE costs for the EU, using the same 
decision tree model as previously reported in the US [7 ? ?ƌĂŶŐĞĨƌŽŵ ? ? ? ?ƚŽ  ? ? ? ?ďŝůůŝŽŶǁŚŝůĞƉƌĞǀĞŶƚĂďůĞĐŽƐƚƐ
ƌĂŶŐĞ ĨƌŽŵ  ? ? ? ? to 7.3 billion (2014 Euros) [8]. However, due to the cost assumptions applied in the study, for 
instance the use of median costs, the total EU cost is likely to be underestimated.  
 
Such epidemiologic modelling studies [3,8] offer valuable insights into the burden of VTE in Europe. To supplement 
these modelling findings, real life observational data are worthwhile. The PREFER in VTE registry was partly set up 
to offer such data. This study assessed the real-life acute and long-term management of patients with VTE, the use 
of health care resources, and provided data to estimate the costs for 12-months treatment following a first-time or 
recurrent VTE diagnosis in hospitals or specialized centers in Europe [4]. In addition, data was collected about clinical 
outcomes, treatment satisfaction, and health related quality of life (HrQoL) resource utilization and absence from 
work.  
 
The aim of this study was to contribute to the current scientific knowledge regarding the burden of DVT in Europe, 
using the PREFER data. The focus is on resource utilization and absence from work. Specific attention is given to the 
differences per country, the difference between patients with active cancer and those without and the association 
between the burden of the disease and baseline patient characteristics. A separate paper concerning mortality and 
health related quality of life of patients with DVT is available elsewhere [9]. 
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Data and methods 
Setting and study population 
The PREFER in VTE registry was a prospective, observational, multicenter study. 3,545 consecutive enrolled patients 
were followed for up to 12 months at 311 active centers in seven European countries including Austria, France, 
Germany, Italy, Spain, Switzerland, and the UK between January 2013 and July 2014. The outline of the study has 
been previously described [4]. Prior to study commencement, the registry protocol was approved by the responsible 
ethics committees for the participating countries and the relevant hospital-based institutional review boards. All 
patients enrolled in the registry first provided written informed consent.  
 
Briefly, patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, 
objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, 
pulmonary embolism or both. Eligible patients were recruited within two weeks of the occurrence of the index event. 
At baseline patients were assessed in terms of their demography, disease, previous clinical events, risk factors, co-
morbidities and presenting PE/DVT symptoms, as well as previous treatments. At 1, 3, 6 and 12 months follow up, 
information regarding the occurrence of clinical events, treatment, resource utilization, health-related quality of life 
and treatment satisfaction during each follow up interval was measured. The current study concerned DVT patients 
only, for which a total of 2,056 patients were recruited in the registry. 
 
Data quality control  
The validity of the data entered into the database was assured by training the investigators on data collection 
ensuring a uniform method. Furthermore, a random audit was performed on the centers included in the registry. 
During these visits the monitor verified informed consent documentation, performed source data verification 
ĂŐĂŝŶƐƚ ƉĂƚŝĞŶƚ ?Ɛ ŵĞĚŝĐĂů ƌĞĐŽƌĚƐ ĂŶĚchecked for the inclusion of consecutive patients at the sites. The data 
collection comprised two different sources. These sources included the hospitals or specialized centers at the time 
of diagnosis of acute VTE and, as hospital based investigators do not always see patients in the following 12 months 
for routine clinical care, patients were also asked to participate in follow-ups by phone, safeguarding the collection 
of resource consumption data. Information was collected directly from the patients during standardized phone calls 
at 1, 3, 6 and 12 months after baseline. The data entered in the database were checked electronically for 
completeness and plausibility at the time of data entry and additional validation was performed on datasets. 
 
Analyses and Statistics 
Descriptive statistics of baseline information are provided by country, including demographics (age, gender, body 
mass index [BMI], marital status and country), clinical factors (with/without previous VTE event, distal vs. proximal, 
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[un]provoked1), previous clinical event (within 3 years prior to enrollment: myocardial infarction, coronary heart 
disease, percutaneous coronary intervention, atrial fibrillation, transient ischemic attack, stroke and bleeding event), 
risk factors (within past 3 months or ongoing: active cancer, prolonged immobilization2, >5 days in bed, varicose 
veins, history of major surgery or trauma,), comorbidities (hypertension, congestive heart failure, vascular disease, 
dyslipidemia, diabetes mellitus, chronic venous insufficiency, renal disease, liver disease, chronic respiratory disease, 
arthritis, lower extremity paralysis, bone fracture/soft tissue trauma, thrombophilia, alcohol use, smoking history, 
and cardiovascular disease), and the presence of DVT symptoms. For regional comparisons, Austria, Switzerland, and 
Germany were combined into one pre-specified region label (DACH). The DACH countries were grouped in a cluster 
as the patient population, practice patterns and healthcare systems were assumed to be similar.  The number of 
sites for Germany, Austria and Switzerland were 74, 5 and 3, respectively.  More detail of clinical variables can be 
found elsewhere [10].   
 
Healthcare resource utilization 
Treatment medications at baseline and each follow up, i.e. the use of heparin (including both low-molecular weight 
heparins and unfractionated heparin), VKA or DOACs, were recorded. Accumulated post-VTE or VTE-related  
healthcare resource utilization, in terms of the number of hospitalizations, duration of hospital stay (LOS), the use 
of intensive care unit (ICU), and ambulatory/office visit at 12 months follow up, was estimated. This accumulated 
post-VTE or VTE-related healthcare resource utilization did not include both the diagnosis of DVT and any 
hospitalization related to the initial DVT. Post-VTE healthcare resource utilization referred to the number of 
hospitalizations, LOS and the use of ICU. VTE-related healthcare resource utilization was specifically for medication 
and ambulatory/office visit. In addition to the total sample, descriptive statistics for country and cancer subgroups 
were also presented. The difference between compared subgroups was evaluated using chi-square test, Kruskal-
Wallis equality-of-populations rank test or Wilcoxon rank-sum test (no normal distribution was assumed), when 
appropriate.  
 
The dependency between baseline characteristics and LOS were examined using zero-inflated negative binomial 
regression to address the issue of the outnumbered zero hospitalization day and over-dispersion of the distribution. 
The zero-inflated negative binomial regression consisted of two parts: the first (inflate) part is to predict whether 
there is an occurrence of LOS (probability of zero or none-zero), whereas the second part is to predict the duration 
of LOS above zero (non-zero value). The examined baseline characteristics included demography factors (age, 
gender, BMI), previous clinical events, clinical factors, co-morbidities, risk factors and presented PE symptoms. 
                                                                
1 Provoked DVT was defined as having prolong immobilization, >5 days in bed, or history of major surgery or 
trauma. 
2 Prolonged immobilization was defined as immobilization within the last 3 months or ongoing (e.g., travelling for 
more than 4 hours). 
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Female specific risk factors, i.e. pregnancy and exogenous estrogen use, were not included in the current analysisas 
potential risk factors in the current analysis in order to permit a single analysis encompassing both genders. A 
separate model was fitted to explore country variation by adding country as an additional co-variate. These analyses 
were limited to the total sample. 
 
Return to work 
Return to work was expressed as the proportion of patients returning to work during the follow up and when they 
returned to work. In the study, patients were asked whether they returned to work during the follow up, and, if 
applicable, how soon they returned to work and their productivity level after return in terms of working hours. The 
analysis was limited to employed patients and an age limit of 65 years at baseline, and a variable indicating how 
soon patients returning to work was derived. Kaplan-Meier survival analysis was executed to present the rate and 
time of employed patients retuning to work. Furthermore, multivariate Cox proportion hazards regression was 
implemented to assess the association between baseline characteristics (the same as those listed above) plus 
country and returning to work.  
 
Missing data  
Due to loss to follow up including death or incomplete information, there was missing data at each cross-sectional 
measurement. No imputation was conducted for any missing value. However, the difference in terms of baseline 
characteristics between patients who completed the follow up questionnaires and those who did not was tested, 
using chi square test, Wilcoxon rank sum test, or t-test when appropriate. 
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Results 
Patients characteristics  
Table 1 presents patient characteristics at baseline stratified by country. Amongst the 2,056 DVT patients at baseline, 
30.3% patients were recruited from DACH, 28.0% from Italy, 18.2% from the UK, 12.0% from Spain and 11.6% from 
France. Mean age differed significantly - with the highest in Italy, approximately 64 years (SD: 16.68) and the lowest 
in DACH, about 57 years (SD: 16.30). Significant differences per country were also found for gender and BMI. More 
than 79% of patients had proximal DVT in Italy, Spain and the UK, whereas the proportion was much lower in France 
(47.5%).  The proportion of patients with provoked DVT was similar across countries (25-31%). Patients in Italy had 
a higher number of previous clinical events and risk factors, as well as the highest comorbidity rates. For example, 
they had higher frequencies of active cancer (15.8%), prolonged immobilization (20.9%) and >5 days in bed (18.5%) 
compared to the other countries. In addition, the prevalence of congestive heart failure, vascular disease, diabetes 
mellitus, renal disease, liver disease, and chronic respiratory disease were also highest amongst patients from Italy.  
The most commonly reported DVT symptoms included pain and swelling, with over 72% and 54%, respectively, 
across all countries. The baseline characteristics of the total sample and cancer subgroup can be found elsewhere 
[9]. 
 
Missing data   
The study sample with complete observations concerning hospitalizations (n=1446) in comparison with those with 
missing data (n=610) showed a higher prevalence of dyslipidemia and a lower prevalence of previous atrial 
fibrillation, cancer, liver disease and chronic respiratory disease. People with missing data were younger, and were 
more likely to smoke. Additionally, data were most often incomplete in the UK. 
 
Healthcare resource utilization 
Medication  
As shown in Table 2, at baseline the proportion of patients initially treated with heparin, vitamin K antagonists (VKA) 
and direct oral anticoagulants (DOACs)s was 64.9%, 42.7% and 26.8%, respectively. (33.5% of patients treated with 
both heparin and VKA.) The use of DOACs was the highest in DACH (54.4%), whereas Spain and Italy had lowest 
rates: 7.0% and 4.0% (p-value<0.0001). (At the time of the data collection of the PREFER in VTE registry, not all DOACs 
were reimbursed in Spain and Italy.) Patients with active cancer were treated differently from those without active 
cancer  ? more heparin treatment was given in patients with active cancer (p-value<0.0001).  In addition, table 2 also 
presents the proportion of patients who continued to use the baseline treatment at 1-, 3-, 6- and 12-months follow 
up. Whereas patients with active cancer continued to use heparin after baseline, >60% up to 3 months, the rate 
dropped to <13% for patients without active cancer. Moreover, amongst the total sample the proportion of patients 
who continued to use VKA or DOACs after baseline were 62.4% and 38.9 % at 6 months and 42.1% and 24.4% at 12 
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months, respectively. More than 17% of patients who continued to use VKA or DOACs had provoked DVT.  In 
comparison to other countries, France, Spain and Italy had a higher proportion of patients who continued to use 
heparin after baseline (21.8, 23.0 and 32.8% at 3 months).  Patients in Spain without active cancer had a higher rate 
of heparin treatment (31.2%, 17.4% and 9.7% for 3, 6 and 12 months).  
 
Post-VTE hospitalization 
Table 3 presents the cumulative frequency (percentage) of post-VTE re-hospitalization and VTE-related 
ambulatory/office visit by cancer and country subgroups. (The average number of visits and LOS can be found in 
Appendix Table 1.) By the end of the 12-month follow up, 197 out of 1552 patients (12.7%) had been re-hospitalized 
(VTE-related). The reasons for re-hospitalization can be found in Appendix Table 2. The average number of repeat 
hospitalizations was 1.4, with an average LOS of 9.9 days (calculated as the total number of days in hospital divided 
by the number of patients who have had hospitalizations). A substantial country variation was observed: the re-
hospitalization rate ranging from 16.7% in Italy to 7.7% in France (p-value <0.0001) and a LOS of 16.6 days in Italy to 
5.2 days in DACH (p-value =0.0001). Figure 1 presents the cumulative percentage of patients who needed re-
hospitalization and the cumulative number of hospital days of those who were hospitalized. From month one the 
hospitalization rate in Italy was substantially higher compared to other countries. We also found that not only were 
patients in Italy hospitalized more often, their hospital stays were longer. The differences between the other 
countries were much smaller. Furthermore, patients with active cancer were more often re-hospitalized than 
patients without active cancer (20.5% vs. 12.2%, p-value=0.037) during the 12-month follow up. However, the 
average LOS was longer for patients without active cancer than for those with active cancer (10.1 vs. 8.2, p-value= 
0.723, Appendix Table 1). 
 
Modeling of risk factors associated with increased length of hospitalization found patients with active cancer, 
previous CAD, chronic respiratory disease, vascular disease, or arthritis were more likely to be hospitalized. When 
modeling for risk factors associated with duration of hospitalization, we found that patients with previous PCI and 
patients living in Italy were likely to have a longer hospital stay. However, with the relative low variance explained 
by the models, the result should be interpreted with caution. Details can be found in Table 4.  
 
VTE-related ambulatory/office visit 
During the 12-month follow up, the majority of patients visited a physician (84.2%), with an average number of visits 
of 7.0 (SD: 7.6). Of those who had at least one visit, the recruiting physician and the general practitioner were most 
often visited: by 69.6% and 55.1% respectively. In comparison, relatively few visits were made to venous institutions 
or other healthcare professionals. Amongst investigated countries, great variation existed in terms physician type 
that patients visited during the follow up period (Table 3). For instance, Spain had a relatively lower percentage of 
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visiting general practitioners, but a higher percentage of visiting internists. In Italy, it was more common to visit 
vascular physicians than in other countries.  In addition, the occurrences of ambulatory/office visits were less in 
patients with active cancer than in those without. Visiting any physician was 72.7% vs. 84.9% in the two groups, 
respectively. 10.0% of the study population did not have any ambulatory/office visit during 12-months follow up; 
the proportion was higher in countries such as Italy 17.4% and the UK 17.1%.  
 
Finally, a possible selection bias should be considered. As noted in the missing data section above, the study sample 
differed from the non-study sample. The additional analyses show that the re-hospitalization rate and average LOS 
at any particular follow up point were higher in the group of patients who did not participate in the next follow up 
compared to those who were followed up.  
 
Return to work 
Amongst 756 patients who were employed at baseline and under 65 years old (average age 46.84), 70.5% had 
returned to work by the end of the one-year follow up. The highest number of patients returned to work in DACH 
(75.85%), the lowest in Spain (61.25%) (p-value= 0.056). Of the active cancer patients, only 32% had returned to 
work after one year (total active cancer sample = 25) (p-value<0.0001). Figure 2 presents the Kaplan-Meier estimate 
of returning to work after the index event in the total study sample (both active and non-active cancer patients). As 
shown in figure 2, more than half of study population had returned to work after a month. The median time for 
returning to work was 34 days. Amongst patients who reported returning to work, 23.4% (120/514) had reduced 
working hours at first return. Initially work hours reduced from an average of 36.8 hours per week prior to DVT, to 
an average of 29 hours per week for the prior 4 weeks of the first assessment. At the time of last follow up 17.6% 
(92/523) continued to have reduced working hours, with an average of 31 hours per week for over the previous 4 
weeks. The data suggested that patients still experienced some level of limited productivity after returning to work. 
The results are presented per country and cancer subgroups in Appendix Table 3.  
 
The Cox regression results suggested that being older, having active cancer, having been in bed for more than 5 days 
is associated with a lower probability of returning to work (OR<1). Adding country variables the results suggested 
that patients in France and Spain were less likely to return to work, whereas patients from Italy were more likely to 
do so. Detailed analysis results can be found in Table 5.  
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Discussion 
This study investigated the burden of DVT in Europe in terms of post-VTE or VTE-related healthcare resource 
utilization and work-loss. The study demonstrated significant country variation in a number of factors. Post-VTE re-
hospitalization rate and LOS varied substantially between countries.  The regression results confirmed the country 
variation in LOS.  In terms of work-loss, half of the employed patients returned to work within a month but around 
thirty percent had still not returned after one year. Active cancer was a significant predictor for not returning to 
work, whereas country also played a significant role in determining their return to work.  
 
Post-VTE or VTE-related healthcare resource use  
Significant country variation in terms of post-VTE or VTE-related healthcare resource use was observed. For example, 
the use of DOACs varied substantially across the countries which can partly be explained by the licensing and 
reimbursement status of DOACs at the time of the data collection (Spain and Italy had limited access). However, 
even amongst the countries where DOACs were fully accessible, DOACs use varied, probably due to different national 
or local guidelines/recommendations. For instance, the UK had a much lower DOAC use, compared to DACH and 
France.  Country variation in the use of heparin after the baseline varied greatly among countries. Patients in France, 
Spain and Italy continued to use heparin after baseline much more often than other countries. After limiting the 
analysis to patients without active cancer, the higher rate of using heparin was still observed in Spain.  Local 
treatment recommendations and limited access to DOACs explain this observation. Furthermore, a large proportion 
of patients who received VKA or DOACs at baseline continued their treatment after 3 months (mostly patients with 
unprovoked DVT, as recommended in the guidelines [11]), where the standard treatment duration according to 
treatment guidelines is usually 3 months, but longer periods of treatment are more often recommended. Thus, the 
proportion of patients who continued to use VKA or DOACs as observed in the data represent those receiving 
extended treatment. It should be noted that the observed medication use in the current study, to a great extent, 
reflected the specific case mix of patients included in the PREFER in VTE registry, as well as the variation in the 
disease management across countries.   
 
Similarly, the frequency of re-hospitalizations and the average length of stay also differs per country, as does the 
frequency of ambulatory/office visits. It may reflect different treatment patterns but it may also be a reflection of a 
different mix of patients. The regression results suggest that after controlling for baseline characteristics of patients, 
patients in Italy were associated with a longer hospital stay in comparison to patients in the UK.  However, it should 
be noted that other factors, such as pressure on budget, cost containment, the healthcare reimbursement system, 
the level of adoption for outpatient VTE treatment in clinical practices, as well as other relevant clinical factors which 
were not recorded in the current study, might all contribute to the observed variations.  
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The key cost driver of the economic burden associated with DVT is VTE-related LOS [12]. While most studies 
examining VTE hospitalization rates and LOS emerged from the US, very few current studies reported those numbers 
in the European setting. A modeling study in France in 1999 reported an average LOS of 3.3-6.4 days [13] and an 
Italian study collecting data from 160 VTE patients in 2010 reported a LOS of 12.5 days [14]. A recent study utilizing 
the data of 1452 DVT patients in Italy from year 2006 to 2013, collected as part of the REITE registry, reported the 
average of LOS as 9 days (SD: 8 days) and the average LOS in 2013 is 7.02 days [15]. In the current study the post-
VTE re-hospitalization was reported. It was not possible to ensure that all hospitalizations were directly related to 
the initial DVT despite the registry asking investigators to record all VTE related re-hospitalizations. A range of new 
hospitalizations under that heading were also collected (Appendix Table 2). 
 
In about 10% of patients there was no recorded follow up visits for DVT. This number is likely due to visits not 
registered as DVT-related. One would expect that DVT patients have regular follow up for other reasons than their 
DVT-history and that visits weren ?ƚƌĞŐŝƐƚĞƌĞĚĂƐƌĞůĂƚĞĚƚŽĂsd. This implies that the resource utilization may well 
be underestimated. The European Society of Cardiology recommends that patients on DOACs are followed on a 
regular basis for on-going review of their treatment, preferably after 1 month initially, and later every 3 months. This 
study demonstrated that patients were followed-up less regularly than recommended by these guidelines. 
 
Return to work 
Our study demonstrated that 70.5% of DVT patients (limited to those employed and under age 65 at baseline) return 
to work within one year, with a lower rate for patients with active cancer. This figure is consistent with return to 
work rate following other major illnesses. The return to work rate within the first year after stroke was reported 
between 45% to 75%, based on self-reported employment outcomes [16,17].  A more recent Swedish publication, 
using insurance sickness leave data, reported return to work rate following stroke was 74.7%, at the end of 6-year 
follow up [18]. Following myocardial infarction (MI), a US study utilizing the data gathered from the VIRGO study 
reported 84% of patients return to work by 12 months [19]. However, this observed high work-loss for patients with 
DVT may at least in part reflect the presence of co-morbidities.  
 
The regression results further suggested that, after adjusting baseline characteristics, patients from France and Spain 
were more likely to return to work compared to patients from the UK, whereas patients from Italy were less likely 
to return to work. This result should be interpreted with caution. It is likely that the results reflect different 
retirement ages, sickness/disability benefits and the prevalence of early retirement across each compared county, 
rather than the impact of DVT alone. Nevertheless, the excess burden adds to the indirect costs and emphasizes the 
need for reducing recurrence rates more effectively and improving the care of DVT patients.  
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Strengths and limitations 
The PREFER in VTE registry provides a rich data source of epidemiology, management and outcomes of VTE patients 
in a real-world setting. It is one of the largest prospective disease registries in VTE and its focus on seven European 
countries provides a much-needed addition to the relatively scarce data on DVT from this continent. In addition, the 
PREFER registry ƌĞƉƌĞƐĞŶƚƐ  ?ƌĞĂů ůŝfĞ ? ĚĂƚĂ ďǇ ŝŶĐůuding consecutive patients presenting with PE/DVT with few 
exclusion criteria, in contrast to data from randomized clinical trials, which typically will include patients with less 
co-morbidities, who are more median aged and where the disease definition is more restricted. In other words, this 
current data represents the real-world practice. To the authors ? best knowledge, there are no other studies that 
have explored country variation in post-VTE or VTE-related HCRU.  
 
However, due to the design of the registry, it is difficult to make a direct comparison between observed countries. 
The results in this registry, nevertheless, are not aiming to accept or reject a predefined hypothesis, they offer a 
reference point to compare other data, such as in more selected patients, data from other countries, data with and 
without the use of DOACs and data in patients with and without cancer. The data may also help in forming 
expectations for future studies when considering subgroups. As such it may be helpful in the further development 
of defining the best treatment pattern/management for DVT patients. Furthermore, a typical limitation of most 
observational studies is that data may be missing. No corrections such as multiple imputations were made, and this 
needs to be considered in the interpretation of the results, as it is likely that the patients with co-morbidities are 
more often missing, and therefore the burden of DVT may be underestimated. A recall bias might play a role in this 
study as the follow-up data was collected through telephone calls few months after the recruitment. Finally, in this 
study the level of significance at 0.05 was used throughout the whole analyses. No adjustment was made in the 
significance level for multiple comparisons. As a result, potential false-positive results cannot be ruled out. 
 
Conclusion  
This study concluded that post-DVT or DVT-related healthcare resource utilization and return to work differed 
markedly between countries and between patients with active cancer and those without. A large amount of country 
specific information on patient characteristics, re-hospitalization, length of hospital stay, ambulatory/office visits 
and work-loss, all of which concern the excess burden of illness for DVT patients was provided to enhance current 
knowledge on health economics in Europe. 
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Table 1 Patient characteristics at baseline 
Baseline 
Total  
n=2056 
France 
n=238 
DACH 
n=623 
Italy 
n=575  
Spain 
n=246 
UK 
n=374     
 
Age, years, mean (SD) 
59.8 
(16.8) 58.6(16.0) 57.4(16.3) 64.5(16.7) 59.3(18.1) 57.6(16.3) *   
Male 52.9 47.9 53.0 49.6 55.7 59.4 *   
BMI, mean (SD) 
27.8  
(5.3) 26.8 (4.7) 28.2(5.2) 26.4(4.9) 28.4(5.0) 29.5(5.9) *   
Highest graduation       *   
Primary school 26.7 19.7 22.5 41.0 48.4 1.9    
Secondary school 47.67 49.6 47.0 41.2 30.5 68.7    
Above  20.91 25.6 21.8 13.9 19.1 28.3    
Marital status       *   
Single 13.8 10.5 18.0 11.8 13.4 17.9    
Married/living as married 65.7 75.2 61.2 66.1 66.7 65.8    
Separated/divorced 5.7 5.0 6.7 3.8 4.1 8.6    
Widowed 10.8 6.7 7.7 17.0 13.4 7.0    
Other 1.1 0.0 1.6 0.9 0.0 1.9    
Previous clinical event  (within 3 yr. prior to enroll.)       
Myocardial infarction 3.1 2.1 1.6 5.4 3.3 2.4 *   
Coronary artery disease 3.8 2.5 2.9 5.9 2.0 4.0 *   
    Percutaneous coronary 
intervention 1.8 0.4 1.3 3.3 0.4 2.1 *   
Atrial fibrillation 2.6 1.3 1.0 5.2 2.4 2.4 * 
Transient ischemic attack 2.0 0.0 0.5 5.1 1.2 1.6 *   
Stroke 2.2 0.8 1.6 3.1 3.3 1.9    
Bleeding event  3.6 3.8 2.9 5.2 3.3 2.4    
DVT symptoms present          
Pain 82.8 88.2 89.1 72.7 83.3 84.2 *   
Discoloration 16.2 6.7 13.6 12.7 19.9 29.4 *   
Calf tenderness 29.4 19.3 15.4 26.1 35.8 59.9 *   
Swelling  73.4 54.2 75.9 65.4 85.0 85.8 *   
Collateral superficial veins 7.3 6.3 3.5 9.9 12.6 6.4 *  
Other 5.8 5.5 3.2 6.4 3.7 11.0 *  
 
 
        
* p-value <0.05 chi-square test, Kruskal-Wallis equality-of-populations rank test, anova  
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Table 1 (continue) Patient characteristics at baseline 
France 
Total  
n=2056 
France 
n=238 
DACH 
n=623 
Italy  
n=575 
Spain 
n=246 
UK 
n=374   
Comorbidities        
Hypertension 39.7 27.7 39.0 49.7 40.4 32.4 * 
Congestive heart failure 2.8 2.9 1.3 6.1 1.6 1.1 * 
Vascular disease 5.5 3.8 2.9 11.7 3.7 2.4 * 
Dyslipidemia 17.5 15.5 11.1 23.8 28.2 12.8 * 
Diabetes 9.7 7.6 10.0 12.4 7.8 8.0  
Chronic venous insufficiency 16.6 18.1 13.7 23.7 25.3 3.7 * 
Renal disease 6.0 3.4 5.3 8.4 4.5 6.1 * 
Liver disease  2.6 2.1 1.1 5.2 1.6 1.9 * 
Chronic respiratory disease 7.6 3.8 3.1 12.2 7.3 10.4 * 
Arthritis 8.8 5.9 2.9 9.7 4.5 21.7 * 
Bone fracture/soft tissue trauma 12.4 13.0 12.7 10.3 9.0 17.1 * 
Lower extremity paralysis 1.2 0.4 1.3 1.0 2.4 0.8  
Alcohol use 18.4 7.6 14.6 11.0 7.8 50.0 * 
Smoking history 30.3 25.6 27.0 30.0 29.0 40.1 * 
Thrombophilia 7.5 5.9 8.8 8.9 7.7 4.3 * 
Cardiovascular disease 62.9 48.1 69.4 66.0 60.9 58.6 * 
Risk factors (within past 3 month or ongoing) 
  
    
Active cancer  8.5 12.2 4.0 15.8 4.9 4.5 * 
Prolong immobilization 15.9 13.0 13.2 20.9 16.3 14.2 * 
>5 day in bed 9.9 6.3 5.8 18.5 11.0 5.3 * 
Varicose veins 22.1 19.3 20.7 24.7 30.5 16.8 * 
History of major surg. or trauma 14.4 18.1 15.0 13.6 12.6 13.4  
Previous VTE event  25.7 33.6 27.4 20.2 21.1 29.4 * 
Proximal 71.3 47.5 63.1 79.3 85.0 78.6 * 
Provoked  27.5 27.3 24.6 31.0 30.1 25.1  
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Table 2 Treatment overtime, by with/without active cancer and country 
  Total sample   
Without  
active cancer 
With  
active cancer 
 % n  % n      % n  
Heparin          
BL 64.9 (1,327 /2,046) 63.1 (1,181 /1,872) 83.9 (146 /174) 
Continue. 1 m  30.5 (345 /1,130) 25.2 (254 /1,009) 75.2 (91 /121) 
Continue. 3 m  18.4 (188 /1,023) 13.8 (128 /927) 62.5 (60 /96) 
Continue.  6 m 10.3 (101 /983) 7.6 (69 /906) 41.6 (32 /77) 
Continue. 12 m  3.8 (35 /928) 2.8 (24 /868) 18.3 (11 /60) 
VKA          
BL 42.7 (874 /2,047) 45.0 (843 /1,873) 17.8 (31 /174) 
Continue. 1 m  94.9 (760 /801) 94.8 (732 /772) 96.6 (28 /29) 
Continue. 3 m  82.1 (588 /716) 82.1 (567 /691) 84.0 (21 /25) 
Continue.  6 m 62.4 (431 /691) 61.8 (413 /668) 78.3 (18 /23) 
Continue. 12 m  42.1 (255 /606) 41.6 (246 /592) 64.3 (9 /14) 
DOACs          
BL 26.8 (549 /2,050) 28.7 (539 /1,876) 5.8 (10 /174) 
Continue. 1 m  92.0 (451 /490) 92.1 (442 /480) 90 (9 /10) 
Continue. 3 m  61.4 (282 /459) 61.7 (277 /449) 50 (5 /10) 
Continue. 6 m  38.9 (169 /435) 38.8 (165 /425) 40 (4 /10) 
Continue. 12 m  24.4 (103 /422) 24.5 (101 /413) 22.2 (2 /9) 
BL: baseline, VKA: vitamin K antagonists, DOAC: direct oral anticoagulants. Heparin includes both low-molecular weight heparins and unfractionated heparin. 
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Table 2 (Continue) Treatment overtime, by with/without active cancer and country 
 France    DAH   Italy   Spain   UK   
  % n     % n    %  n    %  n    %   n   
Heparin                
BL 54.6 (130 /238) 43.7 (269 /615) 72.0 (413 /574) 89.8 (220 /245) 78.9 (295 /374) 
Continue. 1 m  44.1 (49 /111) 17.3 (39 /225) 38.7 (142 /367) 44.9 (87 /194) 12.0 (28 /233) 
Continue. 3 m  21.8 (24 /110) 9.8 (20 /204) 23.0 (72 /313) 32.8 (61 /186) 5.2 (11 /210) 
Continue.  6 m 13.3 (14 /105) 3.1 (6 /192) 12.76 (38 /298) 19.2 (36 /188) 3.5 (7 /200) 
Continue. 12 m  3.1 (3 /96) 0.5 (1 /198) 5.1 (14 /276) 8.3 (14 /168) 1.6 (3 /190) 
VKA                
BL 34.9 (83 /238) 23.2 (143 /616) 50.9 (292 /574) 44.5 (109 /245) 66.0 (247 /374) 
Continue. 1 m  95.0 (76 /80) 94.4 (117 /124) 93.8 (258 /275) 96.0 (97 /101) 95.9 (212 /221) 
Continue. 3 m  76.6 (59 /77) 75.4 (86 /114) 89.5 (214 /239) 88.9 (88 /99) 75.4 (141 /187) 
Continue.  6 m 49.4 (38 /77) 55.1 (59 /107) 73.1 (174 /238) 63.2 (60 /95) 57.5 (100 /174) 
Continue. 12 m  31.9 (23 /72) 43.3 (45 /104) 51.6 (96 /186) 40.5 (36 /89) 35.5 (55 /155) 
DOACs                
BL 42.0 (100 /238) 54.4 (337 /619) 4.0 (23 /575) 7.0 (17 /244) 19.3 (72 /374) 
Continue. 1 m  89.9 (89 /99) 90.9 (271 /298) 95.2 (20 /21) 92.9 (13 /14) 100.0 (58 /58) 
Continue. 3 m  56.1 (55 /98) 59.6 (161 /270) 89.5 (17 /19) 61.5 (8 /13) 69.5 (41 /59) 
Continue. 6 m  30.1 (28 /93) 39.3 (103 /262) 75.0 (12 /16) 33.3 (4 /12) 42.3 (22 /52) 
Continue. 12 m  14.6 (13 /89) 25.2 (66 /262) 41.7 (5 /12) 18.2 (2 /11) 35.4 (17 /48) 
BL: baseline, VKA: vitamin K antagonists, DOAC: direct oral anticoagulants. Heparin includes both low-molecular weight heparins and unfractionated heparin. 
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Table 3. Cumulative post-VTE or VTE-related healthcare resource utilization by cancer/non-cancer and by country  
  Total   Without active cancer With active cancer  
 N= 1552  N= 1464  N= 88 
 n %  N %  n % 
Re-hospitalization  197 12.7% 
 
179 12.2% 
 
18 20.5% 
         
Ambulatory/office visits         
Physician 1307 84.2% 
 
1243 84.9% 
 
64 72.7% 
Original site  910 69.6% 
 
870 70.0% 
 
40 62.5% 
General practitioners 720 55.1% 
 
692 55.7% 
 
28 43.8% 
Cardiologists 71 5.4% 
 
65 5.2% 
 
6 9.4% 
Internists 206 15.8% 
 
201 16.2% 
 
5 7.8% 
Vascular physicians 260 19.9% 
 
241 19.4% 
 
19 29.7% 
Pulmonologists 37 2.8% 
 
36 2.9% 
 
1 1.6% 
Other physicians 293 22.4% 
 
277 22.3% 
 
16 25.0% 
Venous institutions 59 3.8% 
 
56 3.8% 
 
3 3.4% 
Other healthcare professionals 130 8.4% 
 
122 8.3% 
 
8 9.1% 
None 155 10.0%   136 9.3%   19 21.6% 
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Table 3 (continue). Cumulative post-VTE  or VTE-related healthcare resource utilization by cancer/non-cancer and by country  
  France     DACH     Italy     Spain      UK     
 N = 196   N = 500   N = 407   N = 198   N = 251   
 n %   n %   n %   n %   n %   
Re-hospitalization  15 7.7%  52 10.4%  68 16.7%  24 12.1%  38 15.1%  
                
Ambulatory/office visits                
Physician 193 98.5%  457 91.4%  311 76.4%  178 89.9%  168 66.9%  
Original site  167 86.5%  381 83.4%  142 45.7%  118 66.3%  102 60.7%  
General practitioners 132 68.4%  301 65.9%  132 42.4%  65 36.5%  90 53.6%  
Cardiologists 24 12.4%  16 3.5%  18 5.8%  11 6.2%  2 1.2%  
Internists 1 0.5%  66 14.4%  70 22.5%  58 32.6%  11 6.6%  
Vascular physicians 49 25.4%  58 12.7%  101 32.5%  38 21.4%  14 8.3%  
Pulmonologists 6 3.1%  12 2.6%  4 1.3%  13 7.3%  2 1.2%  
Other physicians 65 33.7%  115 25.2%  53 17.0%  42 23.6%  18 10.7%  
Venous institutions 4 2.0%  5 1.0%  39 9.6%  1 0.5%  10 4.0%  
Other healthcare professionals 11 5.6%  31 6.2%  39 9.6%  11 5.6%  38 15.1%  
None -     24 4.8%   71 17.4%   17 8.6%   43 17.1%   
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Table 4 The results of zero-inflated negative binomial regression (length of hospital stay) 
 Coef. Std. Err. P>z [95% Conf. Interval] 
Inflate part    
  
Constant  2.254 0.125 0 2.009 2.498 
Active cancer -0.844 0.305 0.006 -1.442 -0.247 
Previous coronary artery disease -1.154 0.356 0.001 -1.852 -0.456 
Chronic respiratory disease -0.774 0.301 0.01 -1.364 -0.184 
Vascular disease  -1.088 0.300 0 -1.675 -0.500 
Arthritis -0.898 0.266 0.001 -1.419 -0.377 
      
Second part     
  
Constant 1.706 0.130 0 1.451 1.960 
Previous percutaneous coronary 
intervention 
0.812 0.379 0.032 0.069 1.555 
Italy 1.002 0.194 0 0.623 1.381 
The zero-inflated negative binomial regression results suggested that for the first (inflate) part (estimating the probability of having no hospital stay) patients 
with active cancer, previous CAD, chronic respiratory disease, vascular disease or arthritis were associated with a lower probability of having no hospital stay, 
i.e. they were more likely to be hospitalized. The second part of the analyses (estimating non-zero values) found that patients with previous PCI and patients 
living in Italy were likely to have a longer hospital stay. 
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Table 5. Factors determining return to work - Cox regression result  
 Hazard ratios Std. Err. P>z [95% Conf. Interval] 
Age 0.988 0.005 0.009 0.979 0.997 
Active cancer 0.178 0.104 0.003 0.057 0.558 
France 0.593 0.114 0.007 0.406 0.865 
> 5 day in bed 0.610 0.136 0.026 0.395 0.944 
Italy 1.365 0.179 0.017 1.056 1.764 
Spain 0.658 0.118 0.019 0.463 0.935 
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Figure 1. Hospitalization by follow-up and country 
Figure 1.a Percentage of patients being hospitalized  
 
 
M: month 
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Figure 1.b Average total hospitalization duration if hospitalized  
 
 
DACH: Germany, Switzerland and Austria 
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Figure 2. Kaplan-Meier survival estimate of how soon returning to work after index event   
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Appendix 
Table 1. Accumulated post-VTE or VTE-related healthcare resource utilization by each country (magnitude) 
  Total   
Without 
active cancer   
With  
active cancer   France 
 N=1552  N=1464  N=88  N=196 
 n mean SD   n mean SD   n mean SD   n mean SD 
Re-hospitalization                
Number of hospitalization 184 1.4 1.0  
166 1.4 1.0 
 
18 1.3 1.0 
 
15 1.4 1.1 
Length of hospital stay, total 174 9.9 13.3  
156 10.1 13.8 
 
18 8.2 7.6 
 
15 7.8 7.2 
Length of hospital stay, per stay 174 7.1 8.3  
156 7.1 8.4 
 
18 7.2 7.2 
 
15 5.9 4.5 
Days in ICU, total 134 0.2 1.3  
118 0.2 1.4 
 
16 0.2 0.5 
 
12 0.1 0.3 
 
   
 
   
 
   
 
   
Ambulatory / office visits  
   
 
   
 
   
 
   
Any physician 1208 7.0 7.6  
1145 6.9 7.6 
 
63 6.1 6.1 
 
193 6.3 5.6 
    Original site  864 3.6 4.3  
824 3.6 4.3 
 
40 3.3 3.5 
 
167 2.5 1.3 
    General practitioners 674 5.1 6.4  
646 5.1 6.4 
 
28 5.8 5.4 
 
132 3.8 4.5 
    Cardiologists 67 1.3 0.8  
61 1.3 0.7 
 
6 1.8 1.6 
 
24 1.5 1.1 
    Internists 193 2.9 2.8  
189 2.9 2.8 
 
4 1.8 1.5 
 
1 3 - 
    Vascular physicians 242 1.9 1.8  
223 1.9 1.8 
 
19 2.2 1.2 
 
49 1.9 1.4 
    Pulmonologists 36 1.6 1.0  
35 1.6 1.0 
 
1 1 - 
 
6 1.7 0.8 
    Other physicians 278 2.4 2.7  
262 2.4 2.8 
 
16 1.9 2.5 
 
65 2.5 3.7 
Venous institutions 55 2.2 2.2  
52 2.2      2.2 
 
3 1 0 
 
4 1 0 
Any other healthcare professionals 109 8.2 13.7   101 8.0 13.8   8 10.1 12.3   11 9.2 9.6 
ICU: intensive care unit 
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Table 1. (continue) Accumulated post-VTE or VTE-related healthcare resource utilization by each country (magnitude) 
  DACH    Italy   Spain   GB 
 N=500  N=407  N=198  N=251 
 n mean SD   n mean SD   n mean SD   n mean SD 
Re-hospitalization                
Number of hospitalization 50 1.2 0.6  
65 1.6 1.1 
 
23 1.2 0.5 
 
31 1.6 1.4 
Length of hospital stay, total 49 5.2 5.2  
57 16.6 18.2 
 
23 7.3 7.4 
 
30 8.2 13.0 
Length of hospital stay, per stay 49 4.4 4.4  
57 10.6 9.0 
 
23 5.8 5.1 
 
30 6.6 12.3 
Days in ICU, total 43 0.1 0.4  
33 0.1 0.5 
 
19 0.8 3.4 
 
27 0 - 
 
   
 
   
 
   
 
   
Ambulatory / office visits  
   
 
   
 
   
 
   
Any physician 424 9.3 8.3  
285 7.2 9.3 
 
171 4.4 3.5 
 
135 2.6 2.5 
    Original site  362 4.1 4.4  
134 5.9 7.2 
 
116 2.1 1.5 
 
85 1.9 1.5 
    General practitioners 285 6.6 7.0  
125 6.4 8.2 
 
61 2.3 1.9 
 
71 2.2 2.7 
    Cardiologists 15 1.3 0.6  
17 0.9 0.4 
 
10 1.3 0.5 
 
1 1 - 
    Internists 62 4.2 3.5  
64 2.7 2.7 
 
58 2.1 1.7 
 
8 1 - 
    Vascular physicians 53 2.2 2.9  
92 1.9 1.2 
 
37 2 1.6 
 
11 1.2 0.6 
    Pulmonologists 12 1.7 1.3  
4 1.3 0.5 
 
13 1.7 1.0 
 
1 1 - 
    Other physicians 109 1.9 1.4  
49 2.7 3.0 
 
42 3.4 3.4 
 
13 1.5 0.9 
Venous institutions 5 1 0  
36 2.1 1.4 
 
1 1 - 
 
9 3.7 4.4 
Any other healthcare professionals 26 17.4 20.8   31 3.2 6.8   11 12.6 16.9   30 3.4 3.7 
ICU: intensive care unit 
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Table 2. Reasons for re-hospitalization (Multiple choice is possible) 
  % N   
Venous thromboembolism 24.7 (48 /194) 
Myocardial infarction 2.7 (5 /184) 
Transient ischemic attack 1.6 (3 /184) 
Stroke 2.2 (4 /185) 
Arterial embolism 0.6 (1 /183) 
Bleeding event 12.3 (23 /187) 
Major surgery or trauma 25.8 (49 /190) 
Other reasons 66.7 (152 /228) 
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Table 3.  Return to work and working hour/duration, by cancer and country subgroups 
  Total   
Without  
active cancer  
With 
active cancer France    DACH   Italy   Spain   UK   
  n=756   n=731   n=25   n=102   n=265   n=145   n=80   n=164   
Return to work                 
Yes, n 533  525  8  66  201  105  49  112  
No, n 223  206  17  36  64  40  31  52  
First return with reduced work                  
Yes, n 120  118  2  9  31  46  8  26  
No, n 394  389  5  57  159  52  41  85  
First return reduced work, hours                
n 118  116  2  9  30  45  8  26  
Hour per week, mean (SD) 29.0 (14.0) 28.91 (14.0) 32.50 (17.7) 28.83 (10.1) 27.55 (14.6) 32.61 (12.7) 14.38 (18.0) 28.87 (12.8) 
First return reduced work, duration                  
N 109  107  2  9  28  39  8  25  
week, mean (SD) 3.9 (4.4) 3.93 (4.4) 4.00 (5.7) 3.89 (2.6) 4.36 (4.9) 3.74 (4.7) 3.38 (2.1) 3.92 (4.8) 
Current work same as before                 
No, n 92  90  2  9  26  39  4  14  
Yes, n 431  425  6  57  168  64  45  97  
Current work reduced, hours                 
n 92  90  2  9  26  39  4  14  
Hour per week, mean (SD) 31.3 (14.0) 31.24 (14.1) 32.50 (17.7) 28.83 (10.1) 26.42 (14.7) 35.50 (13.5) 22.75 (18.1) 32.50 (12.9) 
Current work reduced, duration                 
n 80  78  2  9  21  33  4  13  
week, mean (SD) 4.3 (4.4) 4.33 (4.5) 4.00 (5.7) 3.89 (2.6) 4.62 (5.4) 3.82 (3.6) 3.50 (1.7) 5.69 (6.1) 
 
 
 
